Antiviral activities of lactoferrin

Antiviral Research

Volumn 52, Issue 3, 2001, Pages 225-239

  Van der Strate, B W A ^a   Beljaars, L ^a   Molema, G ^a   Harmsen, M C ^a   Meijer, D K F ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Antimicrobial properties; Antiviral; Glycoprotein; Lactoferrin

Indexed keywords

ANTIFUNGAL AGENT; AZATHIOPRINE; CIDOFOVIR; IRON BINDING PROTEIN; LACTOFERRIN; METAL; ZINC ION;

ANTIMICROBIAL ACTIVITY; ANTIVIRAL ACTIVITY; BREAST MILK; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; DRUG UPTAKE; HERPES SIMPLEX VIRUS; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE SYSTEM; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; ROTAVIRUS; SPECIES DIFFERENCE; VIRUS INFECTION;

ANIMALS; ANTIVIRAL AGENTS; HUMANS; LACTOFERRIN; MILK; VIRUS DISEASES; VIRUS REPLICATION;

EID: 0034773616     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(01)00195-4     Document Type: Review

References (143)

1. Cytomegalovirus
2. Lactoferrin and cyclic lactoferricin inhibit the entry of human cytomegalovirus into human fibroblasts
3. Structure of human lactoferrin: Crystallographic structure analysis and refinement at 2.8 Å resolution
4. A bactericidal effect for human lactoferrin
5. Role of milk whey in the transmission of human cytomegalovirus infection by breast milk
6. Interaction of lactoferrin, monocytes, and T lymphocyte subsets in the regulation of steady-state granulopoiesis in vitro
7. Lactoferrin: A multifunctional glycoprotein involved in the modulation of the inflammatory process
8. Lactoferrin inhibits the binding of lipopolysaccharides to L-selectin and subsequent production of reactive oxygen species by neutrophils
9. Lactoferrin and the inflammatory response
10. Plasma lactoferrin content: Differential effect of steroid administration and infective illnesses: Lack of effect of ambient temperature at which specimens are collected
11. The antiviral protein human lactoferrin distributes in the body to cytomegalovirus infection prone cells and tissues
12. Identification of the bactericidal domain of lactoferrin
13. Killing of Candida albicans by lactoferricin B, a potent antimicrobial peptide derived from the N-terminal region of bovine lactoferrin
14. Isolated rat hepatocytes bind lactoferrins by the RHL-1 subunit of the asialoglycoprotein receptor in a galactose-independent manner
15. Infectious diseases
16. Viral gastroenteritis
17. Human neutrophil granules and secretory vesicles
18. Cytomegalovirus retinitis in AIDS patients: Influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival
19. Lactoferrin in human milk: Its role in iron absorption and protection against enteric infection in the newborn infant
20. Plasma lactoferrin in patients with neutropenia
21. Lactoferrin acts on I-A and I-E/C antigen+ subpopulations of mouse peritoneal macrophages in the absence of T lymphocytes and other cell types to inhibit production of granulocyte-macrophage colony stimulatory factors in vitro
22. Lactoferrin: Affinity purification from human milk and polymorphonuclear neutrophils using monoclonal antibody (II 2C) to human lactoferrin, development of an immunoradiometric assay using II 2C, and myelopoietic regulation and receptor-binding characteristics
23. The opposing actions in vivo on murine myelopoiesis of purified preparations of lactoferrin and the colony stimulating factors
24. Comparative effects in vivo of recombinant murine interleukin 3, natural murine colony-stimulating factor-1, and recombinant murine granulocyte-macrophage colony-stimulating factor on myelopoiesis in mice
25. Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains
26. Effects of purified iron-saturated human lactoferrin on spleen morphology in mice infected with Friend virus complex
27. Structural interactions between chemokine receptors, gp120 Env and CD4
28. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome
29. Effect of antimicrobial factors in human milk on rhinoviruses and milk-borne cytomegalovirus in vitro
30. Interaction of lactoferrin and lipopolysaccharide (LPS): Effects on the antioxidant property of lactoferrin and the ability of LPS to prime human neutrophils for enhanced superoxide formation
31. Towards a definition of the HCMV entry pathway
32. Regulation of cytokine release from mononuclear cells by the iron-binding protein lactoferrin
33. Role of heparan sulphate proteoglycans in the regulation of human lactoferrin binding and activity in the MDA-MB-231 breast cancer cell line
34. Effects of human lactoferrin on NK cell cytotoxicity against haematopoietic and epithelial tumour cells
35. Summary of the international consensus symposium on management of HIV, CMV and hepatitis virus infections
36. Impairmant of circulating lactoferrin in HIV-1 infection
37. Selective delivery to the liver of antiviral nucleoside analogs coupled to a high molecular mass lactosaminated poly-L-lysine and administered to mice by intramuscular route
38. Ribavirin conjugated with lactosaminated poly-L-lysine. Selective delivery to the liver and increased antiviral activity in mice with viral hepatitis
39. Breast-feeding protects against respiratory syncytial virus infections
40. Antibacterial and antiviral activity of camel milk protective proteins
41. Lactoferrin-lipopolysaccharide interaction: Involvement of the 28-34 loop region of human lactoferrin in the high-affinity binding to Escherichia coli 055B5 lipopolysaccharide
42. The effects of lactoferrin on Gram-negative bacteria
43. Enterovirus type 70 virion and intracellular proteins
44. Hepatotropic conjugate of adenine arabinoside monophosphate with lactosaminated poly-L-lysine. Synthesis of the carrier and pharmacological properties of the conjugate
45. A new role for lactoferrin: DNA binding and transcription activation
46. The role of lactoferrin released by phagocytosing neutrophils in the regulation of colony-stimulating activity production by human mononuclear cells
47. Lactoferrin inhibits herpes simplex virus type-1 (HSV-1) infection to mouse cornea
48. CCR5-mediated human immunodeficiency virus entry depends on an amino-terminal gp120-binding site and on the conformational integrity of all four extracellular domains
49. Suppression of mouse myelopoiesis by administration of human lactoferrin in vivo and the comparative action of human transferrin
50. Studies to define viral cofactors for human immunodeficiency virus
51. Studies of viral co-factors for human immunodeficiency virus in vitro and in vivo
52. Free radicals in inflammatory bowel diseases pathophysiology and therapeutic implications
53. Effect of human milk prostaglandins and lactoferrin on respiratory syncytial virus and rotavirus
54. Bovine lactoferrin is more efficient than bovine lactoferricin in inhibiting HSV-I/-II replication in vitro
55. Protective function of proteins and lipids in human milk
56. Antiviral effects of plasma and milk proteins: Lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro
57. Inhibition with lactoferrin of in vitro infection with human herpes virus
58. Lysozyme, lactoferrin, and secretory immunoglobulin A content in breast milk: Influence of duration of lactation, nutrition status, prolactin status, and parity of mother
59. Concentrations of lactoferrin and iron in human milk at different stages of lactation
60. Antibacterial activity of bovine lactoferrin-derived peptides
61. Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes
62. Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells
63. Lactoferrin, lactoferrin receptors and iron metabolism
64. Coupling of the antiviral drug ara-AMP to Lactosaminated albumin leads to a specific uptake in rat and human hepatocytes
65. Isolation of an iron containing red protein from human milk
66. Human reovirus-like agent as the major pathogen associated with "winter" gastroenteritis in hospitalized infants and young children
67. Replication of hepatitis C virus in cultured non-neoplastic human hepatocytes
68. Inhibition of growth of Candida albicans by iron-unsaturated lactoferrin: Relation to host-defense mechanisms in chronic mucocutaneous candidiasis
69. Roles of CD4 and coreceptors in binding, endocytosis, and proteolysis of gp120 envelope glycoproteins derived from human immunodeficiency virus type 1
70. Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates
71. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis
72. Neutralizing activity in human milk fractions against respiratory syncytial virus
73. Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins B and C, which differ in their contributions to virus attachment, penetration, and cell-to-cell spread
74. Lactoferrin: A general review
75. Antibiotic proteins of polymorphonuclear leukocytes
76. Lactoferrin: Molecular structure and biological function
77. Breast-feeding lowers the frequency and duration of acute respiratory infection and diarrhea in infants under six months of age
78. Association of cell cycle expression of Ia-like antigenic determinations on normal human multipotential (CFU-GEMM) and erythroid (BFU-E) progenitor cells with regulation in vitro by acidic isoferritins
79. Protective influence of lactoferrin on mice infected with the polycythemia-inducing strain of Friend virus complex
80. Longitudinal study of parotid saliva in HIV-1 infection
81. Delineation of the glycosaminoglycan-binding site in the human inflammatory response protein lactoferrin
82. Lactoferrin inhibits herpes simplex virus type 1 adsorption to Vero cells
83. Metal complexes of bovine lactoferrin inhibit in vitro replication of herpes simplex virus type 1 and 2
84. Inhibition of poliovirus type 1 infection by iron-, manganese- and zinc-saturated lactoferrin
85. Studies on lactoferrin, the iron binding protein of secretions
86. Lactoferrin in milk from different species
87. Binding and endocytosis of apo- and holo-lactoferrin by isolated rat hepatocytes
88. Mechanisms for the hepatic clearance of oligopeptides and proteins. Implications for rate of elimination, bioavailability and cell-specific drug delivery to the liver
89. (Glyco)-protein drug carriers with an intrinsic therapeutic activity: The concept of dual targeting
90. Human lactotransferrin: Amino acid sequence and structural comparisons with other transferrins
91. Characterization of hepatitis C virus replication in cloned cells obtained from a human T-cell leukemia virus type 1-infected cell line, MT-2
92. Targeting of drugs to various blood cell types using (neo-) glycoproteins, antibodies and other protein carriers
93. Neoglycoproteins as carriers for antiviral drugs: Synthesis and analysis of protein-drug conjugates
94. Microparticle-enhanced nephelometric immunoassay of lysozyme in milk and other human body fluids
95. Nonspecific oral immunity in individuals with HIV infection
96. Human lactoferrin and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant bacteria
97. The effect of antifungal agents on the in vitro susceptibility of Candida albicans to apo-lactoferrin
98. Human cytomegalovirus infection of breast milk
99. Antibacterial activity of peptides homologous to a loop region in human lactoferrin
100. Augmented inhibition of growth of Candida albicans by neutrophils in the presence of lactoferrin
101. Distribution of lactoferrin and 60/65 kDa heat shock protein in normal and inflamed human intestine and liver
102. Hepatic and extrahepatic clearance of circulating human lactoferrin: An experimental study in rat
103. Cytomegaloviruses of man and animals
104. Nucleotide sequence of human lactoferrin cDNA
105. Antiviral effect of bovine lactoferrin saturated with metal ions on early steps of human immunodeficiency virus type 1 infection
106. Breast-feeding and respiratory syncytial virus infection
107. The secondary multidrug transporter LmrP contains multiple drug interaction sites
108. Lactoferrin metabolism in the rat liver
109. Lactoferrin metabolism in the rat liver
110. Uptake of lactoferrin by the liver. I. Role of the reticuloendothelial system as indicated by blockade experiments
111. Complete nucleotide sequence of human mammary gland lactoferrin
112. Protein-glycosaminoglycan interactions: Infectiological aspects
113. A peptide-model for the heparin-binding property of pseudorabies virus glycoprotein III
114. The pathophysiology of murine retrovirus-induced leukemias
115. Maternal serum lactoferrin and vertical transmission of HIV
116. Lactoferrin-mediated protection of the host from murine cytomegalovirus infection by a T-cell-dependent augmentation of natural killer cell activity
117. Bovine lactoferrin peptidic fragments involved in inhibition of herpes simplex virus type 1 infection
118. A critical site in the core of the CCR5 chemokine receptor required for binding and infectivity of human immunodeficiency virus type 1
119. The influence of cytomegalovirus on the natural history of HIV infection: Evidence of rapid course of HIV infection in HIV- positive patients infected with cytomegalovirus
120. The protein in whey
121. Fungicidal effect of human lactoferrin against Candida albicans
122. Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients
123. Characterization of two kinds of lactotransferrin (lactoferrin) receptors on different target cells
124. Characterization of SA-11 rotavirus receptorial structures on human colon carcinoma cell line HT-29
125. Antirotaviral activity of milk proteins: Lactoferrin prevents rotavirus infection in the enterocyte-like cell line HT-29
126. Antiviral effects of milk proteins: Acylation results in polyanionic compounds with potent activity against human immunodeficiency virus type 1 and 2 in vitro
127. Lactoferrin: Antiviral activity of lactoferrin
128. Charge modification of plasma and milk proteins results in antiviral active compounds
129. A novel sequence found at the 3′ terminus of hepatitis C virus genome
130. 5 of human lactoferrin is essential for binding to heparin, bacterial lipopolysaccharide, human lysozyme and DNA
131. Plasma Lactoferrin levels are decreased in end-stage AIDS-patients
132. Viral load and not lactoferrin concentrations correlates with the transmission of HCMV to the preterm neonate
133. Lactoferrin inhibits HIV-1 replication in vitro and exhibits synergy when combined with zidovudine
134. Cellular receptor structures for pseudorabies virus are blocked by antithrombin III
135. Lactoferrin: A multifunctional glycoprotein
136. Cooperative anti-Candida effects of lactoferrin or its peptides in combination with azole antifungal agents
137. Cytomegalovirus as a possible cofactor in HIV disease progression
138. The cytomegaloviruses: Ubiquitous agents with protean clinical manifestations. II
139. The cytomegaloviruses: Ubiquitous agents with protean clinical manifestations I
140. Anti-infective properties of breast milk
141. Hepatitis C virus envelope proteins bind lactoferrin
142. Lactoferrin uptake by the rat liver: Characterization of the recognition site and effect of selective modification of arginine residues
143. Heparin-binding properties of lactoferrin and lysozyme